Tissue plasminogen activator for the treatment of deep venous thrombosis of the lower extremity: A systematic review

Chest

Volumn 119, Issue 2, 2001, Pages 572-579

  Forster, Alan ^a   Wells, Philip ^a,b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b Clinical Epidemiology Unit   (Canada)

Author keywords

Systematic review; Tissue plasminogen activator; Venous thromboembolism

Indexed keywords

HEPARIN; PLACEBO; TISSUE PLASMINOGEN ACTIVATOR;

BLOOD CLOT LYSIS; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FIBRINOLYSIS; HUMAN; LEG THROMBOSIS; LIMB ISCHEMIA; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS;

EID: 0035110354     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.119.2.572     Document Type: Review

References (29)

1. Long term sequelae of acute venous thrombosis
2. Fibrinolytic therapy for venous thrombosis
3. Fatal pulmonary embolism caused by streptokinase treatment of deep venous thrombosis of the leg?
4. Streptokinase therapy for deep vein thrombosis: A comprehensive review of the English literature
5. A decision analysis of streptokinase plus heparin as compared with heparin alone for deep vein thrombosis
6. Antithrombotic therapy for venous thromboembolic disease: Fifth ACCP consensus conference on antithrombotic therapy
7. Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
8. A strategy of aggressive regional therapy for acute iliofemoral venous thrombosis with contemporary venous thrombectomy of catheter directed thrombolysis
9. Fibrinolytic therapy of deep leg-and pelvic vein thrombosis with various dosages of rt-PA: A pilot study
10. Treatment of acute peripheral thromboembolic disease with the new thrombolytic agent rt-PA (tissue activator of recombinant plasminogen)
11. Comparison of results of fibrinolytic therapy with urokinase, ultra-high dose streptokinase and recombinant tissue-type plasminogen activator in deep vein thrombosis
12. Lysis block technique: A new method of fibrinolytic treatment with tissue-type plasminogen activator (rt-PA)
13. Comparison of dosage schedules of rt-PA in the treatment of proximal deep vein thrombosis
14. Short term response to thrombolytic therapy in deep venous thrombosis: Predictive value of venographic appearance
15. Frequent asymptomatic pulmonary embolism in patients with deep venous thrombosis
16. Loco-regional thrombolysis in deep venous thrombosis
17. Pilot trial of recombinant tissue type plasminogen activator in deep venous thrombosis
18. Loco-regional thrombolysis therapy of deep venous thromboses
19. Specific lysis of an iliofemoral thrombus by administration of extrinsic (tissue-type) plasminogen activator
20. Fibrinolytic therapy of deep vein thrombosis with continuous intravenous infusion of a recombinant tissue plasminogen activator
21. Rt-PA thrombolysis of deep vein thrombosis with different dosages: Results of a prospective multicenter study
22. Thrombolystherapie der tiefen venosen thrombose mit rt-PA
23. Randomized controlled trial of tissue plasminogen activator in proximal deep venous thrombosis
24. Tissue plasminogen activator (rt-PA) vs heparin in deep vein thrombosis: Results of a randomized trial
25. Multicenter pilot study of the efficacy and safety of systemic rt-PA administration in the treatment of deep vein thrombosis of the lower extremities and/or pelvis
26. Double-blind, randomized comparison sf systemic continuous infusion of 0.25 mg vs 0.50 mg/kg/24h of alteplase over 3 to 7 days for treatment of deep venous thrombosis in heparinized patients: Results of the European Thrombolysis with rt-PA in Venous Thrombosis (ETTT) Trial
27. Intermittent regional therapy with rt-PA is not superior to systemic thrombolysis in deep vein thrombosis (DVT): A German multicenter trial
28. Lessons we have learned from the Gusto Trial